A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases

NCT06786338 PHASE2 NOT_YET_RECRUITING

This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients and doctors know what treatment is being given.

Details

Lead sponsor	Suzhou Sanegene Bio Inc.
Phase	PHASE2
Status	NOT_YET_RECRUITING
Enrolment	38
Start date	Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Oct 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• IgA Nephropathy (IgAN)
• C3 Glomerulopathy
• IC-MPGN

Interventions

• SGB-9768

Countries

China